Beximco Pharmaceuticals (LON:BXP) Sets New 52-Week High - Time to Buy?

Key Points

• Beximco Pharmaceuticals reached a new 52-week high stock price of GBX 52.33 ($0.70) during mid-day trading on Tuesday, with a trading volume of 23,275 shares.
• The company maintains a debt-to-equity ratio of 12.47 and a market capitalization of £35.67 billion, indicating stable financial health.
• Beximco Pharmaceuticals, a key player in the pharmaceutical manufacturing sector, began its operations in 1976 and has since transitioned from importing to domestic production of medicines.

Shares of Beximco Pharmaceuticals Limited (LON:BXP - Get Free Report) reached a new 52-week high during trading on Tuesday . The stock traded as high as GBX 52.33 ($0.71) and last traded at GBX 52.33 ($0.71), with a volume of 23275 shares. The stock had previously closed at GBX 49.60 ($0.67).

Beximco Pharmaceuticals Stock Up 0.8%

The company has a market cap of £209.09 million, a PE ratio of 3.29 and a beta of 0.61. The company's 50 day moving average is GBX 41.83 and its 200 day moving average is GBX 39.13. The company has a current ratio of 2.13, a quick ratio of 0.37 and a debt-to-equity ratio of 12.47.

Beximco Pharmaceuticals Company Profile

Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Incorporated in 1976, the Company started its operation by importing products from Bayer, Germany and Upjohn, USA and selling them in the local market. In 1980, Beximco Pharma began manufacturing of these products under licensing arrangement and in 1983 launched its own formulation brands.